Thursday 20 March 2025
The quest for a reliable surrogate marker in vaccine trials has been ongoing, and researchers have made significant progress in identifying potential candidates. A recent study published in arXiv presents a novel approach to rank-based identification of high-dimensional surrogate markers, which could significantly accelerate vaccine development.
To understand the importance of surrogate markers, consider this: measuring the primary outcome of a vaccine trial can be time-consuming, costly, and even impractical or unethical. Surrogate markers offer an indirect way to infer the treatment effect on the primary outcome without directly observing it. This is especially crucial in vaccine trials, where accelerated development and candidate selection are critical.
The researchers developed a method called Rank- Based Identification of high-dimensional Surrogate Markers (RISE), designed for small sample sizes and high-dimensional data typical in modern vaccine experiments. RISE employs a non-parametric univariate test to screen variables for promising candidates, followed by surrogate evaluation on independent data.
The study demonstrates the desirable properties of RISE, including controlled type one error rates and empirical power under various conditions. The method was applied to a clinical trial for an inactivated influenza vaccination, where genes whose post-vaccination expression could serve as a surrogate for induced immune responses were identified. A signature of genes with combined expression at 1 day post-injection appeared to be a reasonable surrogate for neutralizing antibody titers at 28 days after vaccination.
Pathways related to innate antiviral signaling and interferon stimulation were strongly represented in the derived surrogate, providing a clear immunological interpretation. This suggests that RISE can effectively identify biologically meaningful surrogates in vaccine trials.
The sensitivity analysis evaluating the effect of varying non-inferiority margins (ǫ) is particularly noteworthy. As ǫ increases, the number of genes included in the combined marker increases, but so does the p-value. This highlights the trade-off between the robustness and precision of the surrogate marker.
While RISE has shown promising results, its limitations should be acknowledged. The method may not perform well when dealing with complex biological systems or small sample sizes. Additionally, the selection of genes for the combined marker is based on univariate screening, which might not capture interactions between genes or subtle relationships.
Despite these limitations, RISE represents a significant step forward in the development of surrogate markers for vaccine trials. Its potential to accelerate vaccine development and candidate selection could have far-reaching implications for public health.
Cite this article: “Rank-Based Identification of High-Dimensional Surrogate Markers Accelerates Vaccine Development”, The Science Archive, 2025.
Vaccine Trials, Surrogate Markers, Rank-Based Identification, High-Dimensional Data, Small Sample Sizes, Non-Parametric Test, Univariate Screening, Clinical Trial, Influenza Vaccination, Immunological Interpretation
